Interferon-alfa for chronic myeloid leukemia

Slides:

Advertisements

Similar presentations

Discontinuation of Imatinib in Patients with Chronic Myeloid Leukemia Who Have Maintained Complete Molecular Response: Updated Results of the STIM 1 Discontinuation.

Advertisements

Early Molecular and Cytogenic Response Is Predictive for Long-Term Progression-Free and Overall Survival in Chronic Myeloid Leukemia (CML) Hanfstein B.

EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep

Phase III EURO-SKI: Cessation of TKI Therapy Safe, Feasible for Pts Who Achieve Deep Molecular Response New Findings in Hematology: Independent Conference.

Volume 46, Issue 3, Pages (March 2007)

Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial) M. Yoshida, K. Muro, A. Tsuji,

MELD: the holy grail of organ allocation?

Early Molecular and Cytogenetic Response Predict for Better Outcomes in Untreated Patients with CML-CP — Comparison of 4 TKI Modalities (Standard- and.

Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies Gennaro D'Amico, Guadalupe Garcia-Tsao, Luigi.

A 45-SNP genetic risk score is increased in early-onset coronary artery disease but independent of familial disease clustering Morten K. Christiansen,

Volume 23, Issue 1, Pages (February 2014)

A population-based cohort study of the influence of socioeconomic factors and race on survival in Merkel cell carcinoma Reshmi Madankumar, MD, Maressa.

Volume 70, Issue 6, Pages (December 2016)

Retention, dosing, tolerability and patient reported seizure outcome of Zonisamide as only add-on treatment under real-life conditions in adult patients.

Michael A. Pulsipher, Christina Peters, Ching-Hon Pui

In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved Nicolas Novitzky,

Palliative Percutaneous Nephrostomy in Recurrent Cervical Cancer: A Retrospective Analysis of 50 Consecutive Cases Rodrigo Dienstmann, MD, Cristhiane.

Incidence and outcome of Staphylococcus aureus endocarditis—a 10-year single-centre northern European experience H. Asgeirsson, A. Thalme, M. Kristjansson,

Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib by Jorge.

Best Practices in Chronic Myeloid Leukemia by Multidisciplinary Teams

Volume 66, Issue 2, Pages (August 2014)

High GDF-15 Serum Levels Independently Correlate with Poorer Overall Survival of Patients with Tumor-Free Stage III and Unresectable Stage IV Melanoma

Mycobacterial peritonitis: difference between non-tuberculous mycobacteria and Mycobacterium tuberculosis C.-C. Shu, J.-T. Wang, J.-Y. Wang, C.-J. Yu,

John R. Meuleman, MD, William F. Brechue, PhD, Paul S

Living donor liver transplantation: is the hype over?

Arjun Pennathur, MD, Liqiang Xi, MD, Virginia R. Litle, MD, William E

Long-term Cancer-specific Survival in Patients with High-risk, Non–muscle-invasive Bladder Cancer and Tumour Progression: A Systematic Review Sven van.

Mannose-binding lectin gene as a modifier of the cystic fibrosis phenotype in Argentinean pediatric patients Luis Pablo Gravina, Carolina Crespo, Hilda.

Appendectomy is followed by increased risk of Crohn's disease

Patient-reported symptoms and performance status before palliative radiotherapy in geriatric cancer patients (octogenarians) Carsten Nieder, Thomas A.

Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis M. Proesmans, F. Vermeulen,

A population-based cohort study of the influence of socioeconomic factors and race on survival in Merkel cell carcinoma Reshmi Madankumar, MD, Maressa.

Y. Maor, N. Belausov, D. Ben-David, G. Smollan, N. Keller, G. Rahav

A. Solé, P. Morant, M. Salavert, J. Pemán, P. Morales

Volume 53, Issue 1, Pages (January 2008)

Delayed publication of clinical trials in cystic fibrosis

Outcome of Esophagectomy for Cancer in Elderly Patients

The progression of chronic kidney disease: A 10-year population-based study of the effects of gender and age B.O. Eriksen, O.C. Ingebretsen Kidney International

Late outcomes of open heart surgery in patients 70 years or older

Prognostic Impact of Comorbidity in Patients with Bladder Cancer

Elements of design: the knowledge on which we build

Randomized study of imatinib for chronic myeloid leukemia: comparing standard dose escalation with aggressive escalation by Koichi Miyamura, Kazunori Ohnishi,

Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia.

A.H. Gifford Journal of Cystic Fibrosis

Gender differences in treatment outcomes of tuberculosis patients in Taiwan: a prospective observational study J.-Y. Feng, S.-F. Huang, W.-Y. Ting, Y.-C.

Curtailed short-term and long-term survival following infection with non-typhoid Salmonella in Israel M. Weinberger, S. Yaron, V. Agmon, R. Yishai, A.

Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy.

A Post Hoc Sensitivity Analysis of Survival Probabilities in a Multinational Phase III Trial of Decitabine in Older Patients With Newly Diagnosed Acute.

Higher Interleukin-7 serum concentrations in patients with cystic fibrosis correlate with impaired lung function Julia Seyfarth, Sutharsan Sivagurunathan,

Inflammatory and immunological biomarkers are not related to survival in adults with Cystic Fibrosis K.L. Moffitt, S.L. Martin, A.M. Jones, A.K. Webb,

Predictive and Prognostic Markers in Adults With Acute Myeloid Leukemia: A Single- Institution Experience Bolanle Gbadamosi, Daniel Ezekwudo, Sanjog Bastola,

Branford S et al. Proc ASH 2013;Abstract 254.

Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients Valerie Waters, Eshetu G. Atenafu, Annie.

Correlation between time to positivity of blood cultures with clinical presentation and outcomes in patients with Klebsiella pneumoniae bacteraemia: prospective.

Ruth H. Keogh, Sanja Stanojevic Journal of Cystic Fibrosis

Inside This Issue Experimental Hematology

C.P. Kelly Clinical Microbiology and Infection

Pharmacological activation of wild-type p53 in the therapy of leukemia

Outcome of prosthetic knee-associated infection: evaluation of 40 consecutive episodes at a single centre R.R. Laffer, P. Graber, P.E. Ochsner, W. Zimmerli

Is age a predictor of mortality in a UK medical high dependency unit?

Liver transplantation in children

Meta-analysis Shows Extended Therapy Improves Response of Patients With Chronic Hepatitis C Virus Genotype 1 Infection Harald Farnik, Christian M. Lange,

Quality of life in peritoneal dialysis patients: Decline over time and association with clinical outcomes Sr. Anne B. Bakewell, Rob M. Higgins, Mair.

Patients’ inability to perform a preoperative cardiopulmonary exercise test or demonstrate an anaerobic threshold is associated with inferior outcomes.

Age at Repair Affects the Very Long-Term Outcome of Sinus Venosus Defect Giovanni Battista Luciani, MD, Francesca Viscardi, MD, Mara Pilati, MD, Roberto.

Epidemiology and Demographics of Prostatitis

Chronic Myeloid Leukemia: MD-2025 Chisinau, Republic of Moldova

MELD: the holy grail of organ allocation?

Long-term outcome and quality of life of patients requiring multidisciplinary intensive care unit admission after cardiac operations Jean-Louis Trouillet,

Long-term outcomes after nucleos(t)ide analogue discontinuation in HBeAg-positive chronic hepatitis B patients D. He, S. Guo, P. Zhu, S. Tao, M. Li,

Presentation transcript:

Interferon-alfa for chronic myeloid leukemia Michele Baccarani, Domenico Russo, Gianantonio Rosti, Giovanni Martinelli Seminars in Hematology Volume 40, Issue 1, Pages 22-33 (January 2003) DOI: 10.1016/S0037-1963(03)70040-7 Copyright © 2003 Terms and Conditions

Fig. 1 MCgR rate reported from 12 studies of IFNα alone (●)1,6,8,33,35,44,46,47,52,54,59,67,69 and 4 studies of IFNα + LDAC (○)6,32,53,57 plotted against 5-year survival. The relationship is significant (r = 0.662, r2 = 0.439, P = .005). Seminars in Hematology 2003 40, 22-33DOI: (10.1016/S0037-1963(03)70040-7) Copyright © 2003 Terms and Conditions

Fig. 2 Overall survival of 427 patients less than 56 years of age who were enrolled in 2 consecutive ICSG studies of IFNα in CML.44,47 The median follow-up of living patients is 104 months. The graph shows a landmark analysis at 2 years, the calculation including only the patients who were alive and in CP after 2 years. The patients are divided into 3 groups according to the CgR obtained during the first 2 years: major (66%-100% Ph-negative), any other (1%-65% Ph-negative), and none. The difference is very significant (P < .0001, log-rank test). Seminars in Hematology 2003 40, 22-33DOI: (10.1016/S0037-1963(03)70040-7) Copyright © 2003 Terms and Conditions

Fig. 3 Survival according to cytogenetic response and risk score. The patients and the calculations are the same as in Fig 2, but the patients are divided according to Sokal risk score,81 into low risk (A) and non–low risk (B). The cytogenetic response being equal, 10-year survival is better for low-risk patients than for the others. Seminars in Hematology 2003 40, 22-33DOI: (10.1016/S0037-1963(03)70040-7) Copyright © 2003 Terms and Conditions

Fig. 4 As in Fig 3, but the patients are divided into low risk (A) and non–low risk (B) according to the European risk score.35 Low-risk patients survived longer than non–low risk ones, the cytogenetic response being equal. Seminars in Hematology 2003 40, 22-33DOI: (10.1016/S0037-1963(03)70040-7) Copyright © 2003 Terms and Conditions

Fig. 5 Selecting the complete cytogenetic responders stresses even more the importance of the risk as an independent indicator of a long survival. All of the patients had achieved the best possible cytogenetic response to IFNα (complete), but 10-year survival was close to 100% for low-risk patients v less than 50% for the others, either using the risk definition according to Sokal (A) or the European risk score (B). Seminars in Hematology 2003 40, 22-33DOI: (10.1016/S0037-1963(03)70040-7) Copyright © 2003 Terms and Conditions